Microglia represent a crucial cell population in the central nervous system, participating in the regulation and surveillance of physiological processes as well as playing key roles in the etiologies of several major brain disorders. The ability to target gene transfer vehicles selectively to microglia would provide a powerful new approach to investigations of mechanisms regulating brain pathologies, as well as enable the development of novel therapeutic strategies. In this study, we evaluate the feasibility of specifically and efficiently targeting microglia relative to other brain cells, using vectors based on two different serotypes of adeno-associated virus (AAV) carrying cell-type-specific transcriptional elements to regulate gene expression. Among a set of promoter choices examined, an element derived from the gene for the murine macrophage marker F4/80 was the most discriminating for microglia. Gene expression from vectors controlled by this element was highly selective for microglia, both in vitro and in vivo. To our knowledge, this is the first demonstration of selective expression of transferred genes in microglia using AAV-derived vectors, as well as the first utilization of recombinant AAV-5 vectors in any macrophage lineage. These results provide strong encouragement for the application of these vectors and this approach for delivering therapeutic and other genes selectively to microglia.
Introduction
Microglia, the brain's resident macrophages, are a crucial if minor component of the central nervous system (CNS), representing up to 10% of adult brain cells. In the CNS, microglia participate in the regulation of diverse physiological processes by controlling the development, growth, and function of other brain cells. In addition, microglia constitute a key immune surveillance system responsible for destroying infectious agents, removing cell debris, and promoting brain tissue repair. As a consequence of their surveillance functions, microglia become activated in response to many different pathologic processes in the CNS, including AIDS dementia, Alzheimer's disease, multiple sclerosis, ischemia, and Creutzfeldt-Jakob disease. In turn, inappropriate or chronic over-activation of microglia is believed to play a key role in advancing the pathologies of several of these diseases. In addition, microglia represent the major cell type in the brain susceptible to infection by HIV. Owing to their central roles in controlling brain injury and disease, and their susceptibility to subversion in a set of diverse, clinically important pathogenic processes, microglia constitute a pivotal population for study in basic brain research, as well as for advancing the goal of gene therapy for CNS disorders.
Attempts to genetically manipulate primary hematopoietic cells have principally focused upon transferring genes into pluripotent stem cell populations. Relatively little emphasis has been given to targeting more mature myeloid lineages, in large part because they are strongly refractory to most types of gene transfer vehicles, even in vitro. Similarly, gene transfer into brain cell populations has focused largely upon the neurons. Nevertheless, some meaningful if tentative steps in the direction of engineering microglia have been taken. Implantation of ex vivo engineered microglial cell lines, or precursor cells, has been successfully performed in several animal models. 1, 2 In another novel approach, engraftment into mouse brain of a neural stem cell line engineered to shed a retroviral vector resulted in gene transfer into the microglia compartment. 3 To approach this task, we elected to use recombinant vectors based upon adeno-associated virus (rAAV) as gene transfer vehicles. AAV represents a small family of replication-defective human parvoviruses not associated with any pathologies. Typical AAV vectors retain none of the viral coding sequences, 4 are nontoxic, and exhibit low immunogenicity, 5, 6 in marked contrast with other classes of viral vectors (adenoviruses, herpes simplex virus). [7] [8] [9] The packaging limits of AAV-derived vectors are comparatively small (about 5.5 kb), making inclusion of very long genomic DNA sequences impractical, but this is still fully adequate for many applications. rAAV can be employed to transfer genes into cells of human origin as well as those of other primates and rodents. In human cells, the wild-type AAV genome integrates specifically within a short region of chromosome 19. However, vectors deleted for the viral coding sequences integrate slowly and nonspecifically by a different mechanism. 10 Therefore, rAAV-delivered transgenes persist in target cells as a mixture of stable episomes and genuine integrants, the relative proportions of which vary depending upon the cell type. However, unlike retroviruses, the episomal forms are also actively transcribed.
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While the efficiency of rAAV-mediated gene transfer varies widely between different cell types, this class of vector has been used successfully to transduce several primary cell types and tissues which are refractory to most viral vectors, including striated muscle, liver hepatocytes, and vessel endothelium. 5, 6, 12, 13 Of particular relevance for this study, rAAV have been employed with good success by many groups to deliver genes into neuron populations in vitro and in cultured brain sections, 14 as well as in the intact mammalian CNS. [15] [16] [17] [18] Also, while there has been little exploration of the utility of rAAV to effect gene transfer into differentiated macrophage populations, such as microglia, we previously employed an rAAV successfully on mature alveolar macrophages, as well as peripheral blood monocytes. 12, 19 Most rAAV generated to date have been derived from serotype 2 of the virus. In vivo, transduction with rAAV-2 vectors in the brain tends to occur primarily into the neurons, 15, 20 in contrast to the in vitro situation, where astrocytes and oligodendrocytes are also readily transduced. 21, 22 However, successful targeting of an rAAV-2 to oligodendrocytes in intact brain has also been reported, using the vector in concert with a strongly cell-typespecific promoter. 22 More recently, as additional serotypes of AAV have been cloned and characterized, vectors derived from several other types of AAV have begun to be exploited. Sequence alignments and other analyses indicate that AAV-5 is the most divergent of the known serotypes of AAV. 23, 24 Of particular note, rAAV-5 vectors appear able to deliver genes not only into neurons, but other major brain cell populations in vivo, such as astrocytes, to a degree more comparable to their capabilities observed in vitro.
Although other strategies are under active development, presently, the most reliable way to restrict expression of a vector transgene to particular cell types is at the transcriptional level. In addition to cell-type selectivity, the inclusion of cell-type-specific regulatory elements in rAAV vectors can provide additional advantages for gene delivery purposes. 22 In contrast to highly active viral promoters such as CMV-IE, the use of cell-type-specific mammalian promoters can permit the synthesis of transgene proteins in concentrations closer to physiologically meaningful levels. Also, the phenomenon of promoter silencing, characteristic of promoters such as CMV-IE in vivo, 15 can often be avoided by using more cell-restricted mammalian elements, as for example by employing the neuron-specific enolase (NSE) promoter to induce expression in neurons. 16 To generate microglia-specific AAV-derived vectors, we constructed isogenic vectors from serotypes 2 and 5 in which expression was controlled by regulatory elements derived from genes encoding several different myeloid-specific antigens: human CD11b and CD68, as well as murine F4/80. The properties of these vectors were compared, and contrasted against control vectors driven by the high level, nondiscriminatory CMV-IE promoter. Transgene expression was monitored in each case using two distinct and complementary indicator genes, lacZ and red fluorescent protein (RFP). Expression from each vector was evaluated in vitro in microglia vis-à-vis other brain cells, as well as in a different macrophage lineage.
Among the regulatory elements evaluated, the element derived from the F4/80 sequence yielded the highest level of specificity for microglia in primary cultures in vitro, and provided a similar level of selectivity in the intact rat brain. Combined with the other unique properties of AAV, these results provide a strong foundation for a workable approach to effecting microglia-specific gene transfer in living animals.
Results

Vector design and construction
To attempt to restrict the expression of rAAV transgenes to microglia, several candidate transcription elements were selected for the study. The tissue specificities and expression patterns of the human CD11b and CD68 antigens, as well as the murine F4/80, have been analyzed in different types of myeloid cells, and each has been identified as a specific marker of particular myeloid lineages including, to varying degrees, microglia. [25] [26] [27] [28] The regulatory as well as coding sequences of each gene have also been cloned. [28] [29] [30] The first candidate, CD11b, the a subunit of the CD11b/CD18 integrin adhesion molecule, is not present on the surfaces of immature myeloid precursors, but expression increases during early cell differentiation and is subsequently restricted to mature monocytes, macrophages, neutrophils, natural killer cells, and microglia. 26, 29 CD11b is also expressed at low levels in a few other cell types, including fetal liver stem cells, activated/memory CD8 + T cells, and B1 B cells. It has been confirmed that this specificity of CD11b expression is exerted at the transcriptional level, using a model of undifferentiated human myeloid leukemic cell lines.
The second candidate, CD68, a lysosome-associated membrane glycoprotein, is present during early granulomonopoietic differentiation and then becomes markedly upregulated in cells of several monocytic lineages, including tissue macrophages, blood monocytes, and, to a lesser extent, microglia.
27 CD68 expression has also been noted in several types of nonmyeloid cells, including lymphocytes, neutrophils, and megakaryocytes, although at much lower levels.
The third promoter selected, derived from the murine F4/80 gene, is the least characterized of the set. F4/80, a transmembrane spanning cell surface molecule, is a highly specific marker for macrophages.
28 F4/80 is expressed early during development 28 although later in myeloid differentiation than CD11b, but is more tightly restricted to myeloid lineages. Anti-F4/80 antibodies react specifically with mouse tissue macrophages (from the peritoneum, liver, spleen, kidneys, skin epidermis, and thymus), macrophages derived from cultured bone Targeting transgene expression to microglia with AAV M Cucchiarini et al marrow precursors, and microglia. 25, 28, 31 F4/80 is also expressed at low levels on blood monocytes, 31 but is absent from the surfaces of other related cell types, including dendritic cells, polymorphonuclear leukocytes, lymphocytes, osteoclasts, and fibroblasts.
To monitor the specificities of gene expression from rAAV bearing these different promoters, two distinct and complementary reporters were employed, the conventional lacZ marker encoding b-galactosidase (b-gal) and the more recently developed RFP. 32 The use of two different genes was included to avoid over-reliance upon a single indicator, and control for complications in interpretation that might arise from endogenous background contributions to either transgene signal. Unlike the case with b-gal, the fluorescent signal of RFP is also readily detectable in living cells.
Each myeloid-specific promoter was inserted upstream of the lacZ gene in AAVb-gal (2/CMV-IE-lacZ), an AAV-2-derived vector plasmid, 19 replacing the CMV-IE promoter in that construct. The resulting vectors, 2/ CD11b-lacZ, 2/CD68-lacZ, and 2/F4/80-lacZ, are diagrammed in Figure 1 . The corresponding AAV-5-derivatives 5/CMV-IE-lacZ, 5/CD11b-lacZ, 5/CD68-lacZ, and 5/F4/80-lacZ were constructed by substituting the Rous sarcoma virus (RSV) promoter present in vector plasmid pAAV5LacZ24 with each of the different myeloidspecific regulatory elements, or a CMV-IE promoter.
An RFP expression cassette (*RFP) was then inserted into each of these vector constructs in place of the lacZ marker, to produce matching sets of AAV-2 (2/CMV-IE-*RFP, 2/CD11b-*RFP, 2/CD68-*RFP, and 2/F4/80-*RFP) and AAV-5 derived vector plasmids (5/CMV-IE-*RFP, 5/ CD11b-*RFP, 5/CD68-*RFP, and 5/F4/80-*RFP) carrying the RFP coding sequence.
Packaging of each vector plasmid into virions was performed as described in Materials and methods.
rAAV transduction of microglia and other brain cell populations
To test the feasibility of delivering and expressing rAAVdelivered transgenes in microglia, while restricting their expression within other brain cell populations, primary cultures of microglia were prepared from developing rat brains. Purities of the cell preparations were at least 90%, as assayed by immunocytochemistry for cell-type-specific markers. The cultures were then transduced with each set of AAV-2 and AAV-5-derived vectors. Figure 2 shows the results of X-Gal staining performed on cultured microglia 5 days after transduction with each vector. In cells exposed to either 2/CMV-IE-lacZ ( Figure  2b ) or 5/CMV-IE-lacZ (Figure 2f ), very high levels of transgene expression were detected, in contrast to the untreated control cells (Figure 2a) , in which the background staining was very low to undetectable. b-gal activity was also detectable in cells transduced with the otherwise isogenic rAAV in which expression was driven by one of the three myeloid-specific promoters. However, major differences in the levels of expression were noted between the three promoters. In particular, the F4/ 80 element induced detectable transgene expression in approximately 25% of the treated microglia, the CD68 element in a maximum of 10% of the cells, and the CD11b element in one cell or less per field, when the transgene cassettes were delivered in the context of AAV-5-derived vectors. In most instances, the numbers of positive cells trended slightly higher in cultures exposed to rAAV-5 vectors than their rAAV-2 counterparts, despite the equivalent titers of the vector preparations, but the differences were not statistically significant. Prior activation of the cultures with rIFN-g, a proinflammatory cytokine and a prime macrophage activator, did not alter the relative rankings or extent of the gene expression (not shown). 33 Similar results were obtained in experiments performed with sets of rAAV expressing the RFP indicator, as evaluated by confocal microscopy of treated microglia cultures. Intense fluorescence was observed using either 2/CMV-IE-*RFP or 5/CMV-IE-*RFP (Figure 3c and g ), compared to untreated cells, while the proportions of fluorescent microglia observed after exposure to rAAV-*RFP bearing the myeloid-specific promoters were very similar in each case to the numbers of stained cells seen following treatment with the corresponding lacZ vectors (see representative results from day 5 post-transduction in Figure 3 ). Together these results demonstrated efficient rAAV-mediated gene transfer into microglia, and confirmed that the patterns of expression seen with different promoter elements were not dependent upon the gene being transferred.
To determine the specificity of expression from rAAV bearing each of these promoter elements in other brain cell types, cultures of primary rat neurons or astrocytes were prepared from embryonic striatum, and exposed to rAAV under conditions similar to those employed for the microglia. Representative results in neurons, using vectors expressing RFP, are shown in Figure 4 . Addition Targeting transgene expression to microglia with AAV M Cucchiarini et al of vectors of either serotype to neurons resulted in intense fluorescence in most of the cells when expression was driven by the CMV-IE element, even at a low input dose. No differences in expression were noted between rAAV-2 and rAAV-5 vectors. However, in marked contrast to the observations in microglia, RFP expression in neurons was undetectable after treatment with vectors driven by any of the myeloid-specific promoters. Use of lacZ instead of RFP as the indicator yielded the same outcome. Closely parallel findings were obtained when primary astrocytes were exposed to a set of the vectors. Expression from a vector was detected in astrocytes only Targeting transgene expression to microglia with AAV M Cucchiarini et al when the transgene was controlled by the CMV-IE promoter, and not by any of the myeloid-specific elements. These dramatic differences between vector expression in primary microglia, as opposed to neurons or astrocytes, were reproducible between different cell preparations, and when different time points were evaluated. Although each cell type was demonstrably susceptible to AAV transduction, expression of the gene cassette could be induced in microglia even as it was blocked in neurons and astrocytes, by careful selection of the promoter driving the transgene.
rAAV transduction of other tissue macrophages
The vector sets were next tested upon primary macrophages from a very different lineage, to further evaluate the myeloid-specific character of each promoter in the context of rAAV. Mature human lung alveolar macrophages purified from broncholavage fluids were selected because we have previously established their susceptibility to transduction with rAAV-2.
12,17 Figure 5 shows the results of confocal analyses performed on alveolar macrophages 3 days following transduction with the different vectors expressing RFP. High levels of fluorescence were detected in cells transduced either with 2/ CMV-IE-*RFP (Figure 5c ) or with 5/CMV-IE-*RFP (Figure 5g ), compared to untreated cells (Figure 5a ). Strong transgene expression was also observed when the RFP sequence was controlled by either the CD11b promoter (Figure 5d and h) or by the CD68 promoter (Figure 5e and i) . As was noted in the microglia studies, expression trended higher after exposure of macrophages to rAAV-5 vectors compared to their rAAV-2 counterparts, but the differences noted were small. As with the microglia, no changes in expression patterns were noted following treatment of the cells with rIFN-g (not shown).
However, in marked contrast to the results in microglia, no expression was detected from either rAAV-2 or rAAV-5 vectors when the indicator was under the control of the F4/80 promoter. Similar findings were obtained using rAAV-2 and rAAV-5 vectors expressing lacZ. Also striking was the failure of the F4/80 regulatory element to induce any transgene expression in this cell population, either in the context of AAV-2 (Figure 5f ) or AAV-5 (Figure 5j) , despite inducing the highest levels of transgene expression in microglia of any of the myeloid-specific promoters. The F4/80 promoter therefore represented the most specific element evaluated for transduction of resident brain macrophages, as opposed to either other brain cell populations or other macrophages.
rAAV-mediated gene transfer in vivo
The ability to restrict expression of an AAV-delivered transgene to microglia vis-à-vis other brain cell types in vivo was evaluated next, employing one of the vectors characterized in vitro as exhibiting the highest specificity for microglia. 5/F4/80-*RFP was delivered by stereotaxic injection into the striatum of male Sprague-Dawley rats. Brain sections were subsequently collected at two time points, and processed for histological analysis. Double immunostaining was performed using specific antibodies against RFP and the F4/80 surface marker ( Figure  6 ). In brains collected 3 days after injection, little or no RFP expression was detected. However, in brains collected 3 weeks postinjection, the RFP marker was easily visualized (Figure 6b ) and was seen to colocalize with the F4/80 antigen in cells around the injection site Targeting transgene expression to microglia with AAV M Cucchiarini et al
Discussion
The capability to genetically manipulate microglia populations with ease would lead directly to new avenues for exploration into the etiologies of multiple brain pathologies, as well as afford opportunities for gene therapy approaches to some of these disorders. Unfortunately, most classes of viral vector have proven to be poor agents to transfer genes into microglia and other myeloid lineages. One possible exception are vectors derived from complex lentiviruses, such as HIV, 35, 36 which naturally target this cell type. However, most such vectors also carry significant stretches of native viral coding sequence, because their packaging signals are embedded within viral open reading frames. For clinical applications, they are also freighted by additional safety considerations associated with using agents derived from pathogenic viruses.
Technologies based on rAAV have proven to be powerful tools for delivering genes into several organ systems, and most prominently for targeting brain cells. [15] [16] [17] [18] The susceptibility of microglia to infection by AAV-2 was originally suggested by Bartlett et al 37 using wild-type virus. The presence of the AAV was detected in microglia following stereotaxic injection of Cy3-labelled virions into rat brain, although preferential binding and uptake by neurons occurred to a much greater extent and at much earlier times (minutes instead of hours), and they were unable to detect AAV gene expression in the microglia. Using an in vitro system, we confirmed the permissivity of primary microglia to rAAV transduction and were able to detect high levels of transgene expression in these cells, using two different reporter genes placed under the control of the strong heterologous CMV-IE promoter, instead of the much weaker AAV p5 promoter, which controls expression of the major viral proteins in wild-type AAV.
We then employed two strategies to circumvent the preference for neurons characteristic of classic rAAV-2 vectors. First, we constructed AAV-5-derived vectors, which transduce the major brain cell populations in vivo with less selectivity compared to rAAV-2.
15,20 Using rAAV-5 vectors, we observed transduction efficiencies in microglia in vitro at least as high as those achieved with equivalent titers of rAAV-2. Second, we generated vectors carrying myeloid-specific promoters in order to restrict gene expression to these cells, a strategy previously employed in retroviral 38 and adenoviral vectors. 39 Among the promoters tested, the element controlling expression of the murine F4/80 resulted in the highest levels of transgene activity in the microglia, while simultaneously exhibiting the maximum discrimination against expression in another type of macrophage. Several other studies have suggested that F4/80 is the most reproducible and specific antigen for detection of this cell type, 26, 28, 40 compared with either CD11b, 26, 41 or CD68. 41, 42 Unexpectedly, gene expression driven by the CD11b and CD68 promoters in transduced microglia was notably muted, particularly in the case of CD11b. The absence of more robust transgene expression from these elements in microglia was not due to a lack of sequences necessary for promoter activity per se, or the presence of poison sequences, as demonstrated by the much higher levels of expression from transgenes driven by either CD11b or CD68 noted in human alveolar macrophages. The results in alveolar macrophages confirmed the basic functionality of the CD11b and CD68 promoter fragments employed, as well as affirming the high specificity of the F4/80 element for microglia. The latter result is also in accord with previous studies showing very low or undetectable levels of F4/80 in alveolar macrophages. 28 It is possible that the low expression levels achieved in rat microglia using the CD11b and CD68 elements were because of deficiencies of the human promoter sequences in rodent cells. However, this seems unlikely. Strong transgene expression from the human CD68 promoter has been described in murine macrophages, 39 and transgenic mice bearing gene cassettes under the control of the human CD11b promoter exhibited vigorous expression of the transgene product in their macrophages. [43] [44] [45] The disparities between expression of native gene products and production from a heterologous transgene driven by the isolated promoter may relate to additional sequences that contribute to maximal expression in microglia. For example, Greaves et al 30 demonstrated that the human CD68 sequence lies directly downstream of the eIF4A1 gene. Some additional far-upstream regulatory sequences may thereby contribute to the cell-type specificity of the native CD68 product. Similarly, the macrophage specificity of the native CD11b promoter has been reported to be fully contained within a fragment extending from bp À412 to bp +83, 29 but expression of CD11b-driven transgenes has not been detected in microglia of transgenic animals, even when longer gene fragments were employed.
These results represent the first demonstration of gene transfer into primary microglia using an rAAV, as well as the first successful use of rAAV-5 in any macrophage lineage, and show that it is practical to potently suppress transcription from vector-delivered transgenes in neurons, while permitting it in another brain cell type. Direct injection of an rAAV vector carrying the F4/80 element also demonstrated the feasibility of genetically manipulating microglia in vivo. In this study, sustained and restricted transgene expression was observed in microglia 3 weeks postinjection, but not after 3 days. This time lag in the appearance of RFP is in good agreement with reports by other investigators characterizing AAVmediated gene transfer into neurons and other cell types in vivo. 16, 22, 46 The stringency of the restriction to microglia imposed by the F4/80 element, observed both in vitro and in vivo, is particularly impressive considering the exquisite susceptibility of neurons to uptake of AAV. Transduction efficiencies observed with the different rAAV on microglia were similar to those of the alveolar macrophages, with both myeloid cell types requiring about 10 Â higher vector input doses, compared with neurons, to achieve similar effects.
Taken together, these results provide strong encouragement for the further examination of recombinant AAV vectors for targeting therapeutic genes to microglia, and should lead to valuable applications for experimental brain research as well as for gene therapy. Several attempts have also been made recently to redirect the host cell tropism of AAV-2 by inserting short peptide ligands into the sequence of the capsid protein VP3, the major constituent of the virion. [47] [48] [49] [50] These served both to inactivate the natural broad tropism of the virus, and
Targeting transgene expression to microglia with AAV M Cucchiarini et al confer new binding affinities for particular cell-surface receptors. As X-ray crystallography data about the structure of the AAV-2 capsid is becoming available, the outcomes of such manipulations should become more predictable in the very near future. As the knowledge base about the capsid structures of different types of AAV continues to expand, such approaches, combined with careful choice of regulatory elements in the delivered transgenes, should lead in the near future to bona fide 'designer vectors' exhibiting both high-affinity and very tight selectivity for their cellular targets.
Materials and methods
Cells
The 293 line, an adenovirus-transformed human embryonic kidney cell line was maintained in Eagle's minimal essential medium (Mediatech cellgro, Herndon, VA, USA) containing 10% fetal bovine serum (FBS) (Gibco BRL Life Technologies, Grand Island, NY, USA) and 100 U/ml-100 mg/ml penicillin-streptomycin (penstrep).
Primary rat microglia cultures were prepared from the cortices of 1 to 2-day-old neonatal Wistar rats as previously described 51, 52 and maintained in DMEM/F-12 (Gibco BRL Life Technologies), 10% FBS, pen-strep at 371C under 5% CO 2 . Under the conditions of preparation, the cultures were 95-99% pure, as characterized by immunocytochemistry for the microglia marker ED-1. Prior to transduction, the microglia were cultured for 2 days in 24-well plates on microscope coverglasses (Fisher Scientific, Pittsburgh, PA, USA; cat. no. 12-545-80) precoated with 0.2 mg/ml poly-D-lysine (Sigma, St Louis, MO, USA; cat. no. P6407) at a density of between 1 and 2 Â 10 5 microglia well. For activation, the cells were incubated with 100 U/ml of recombinant human IFN-g (rIFN-g) (Sigma; cat. no. I3265) for 48 h at 371C 3 days following rAAV transduction. 27 Rat primary neuronal cultures were prepared from embryonic day 17-18 rat striatum as previously described 53 and maintained in DMEM/F-12, with 1 Â B27 supplement (Gibco BRL Life Technologies), pen-strep at 371C under 5% CO 2 . Cells (2 Â 10 6 ) were grown in 12-well plates on microcoverglasses (VWR Scientific Products, West Chester, PA, USA; cat. no. 483-046) precoated with 0.2% polyethylenimine (Sigma; cat. no. P3143) in 0.05 M Na 2 B 4 O 7 Á 10H 2 O pH 8.4 for 2 days prior to rAAV transduction. The ratio of cells staining positive histochemically for NSE versus glial fibrillary acid protein (GFAP) was greater than 10 : 1.
Human primary lung alveolar macrophages were prepared from bronchoalveolar lavages as previously described 12 and cultured in RPMI 1640 (Mediatech cellgro), 10% FBS, pen-strep at 371C under 5% CO 2 . Cells (0.4 Â 10 6 ) were grown in 12-well plates on micro coverglasses precoated with 0.2 mg/ml poly-D-lysine for 2 days prior to rAAV transduction. For activation, the cells were incubated with 1000 U/ml of rIFN-g for 24 h at 371C 2 days following rAAV transduction.
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Plasmids
The AAV-2-derived vector plasmids used in this study were derived from a parental genomic clone, pSSV9, obtained from RJ Samulski, as was pAd8, a helper plasmid containing the AAV-2 replication and encapsidation functions. 4, 55 The AAV-5-based plasmids were derived from pAAV5LacZ, provided by JA Chiorini, as was 5RCB, a helper plasmid containing the AAV-5 replication and encapsidation functions. 24 2/CMV-IElacZ is an AAV-2 vector plasmid containing the lacZ gene under the control of the cytomegalovirus immediateearly promoter (CMV-IE) and the simian virus 40 (SV40) small t antigen intron/polyadenylation signal (SVpA), which has been described previously as AAVb-gal. 19 A 496-bp segment of the CD11b promoter sequence, extending from position À412 to +83 of the human CD11b gene was provided by DG Tenen. 29 A CD68 regulatory element, consisting of the 460-bp sequence upstream of the start codon of CD68, followed by the first intron of the gene (83 bp) that acts as a macrophagespecific enhancer, was provided by DR Greaves. 30 The F4/80 promoter fragment, comprised of the 667 bp immediately upstream of the start site of translation, was provided by A McKnight. 28 The Red Fluorescent Protein RFP expression cassette (*RFP) was derived by PCR amplification from plasmid pDsRed1-N1, encoding the Discosoma sp. red fluorescent (Clontech Laboratories, Palo Alto, CA, USA; cat. no. 6921.1). *RFP incorporated (1) a 22-bp leader/Kozak element, (2) a synthetic 48-bp in-frame sequence containing a (gly) 4 motif followed by a nucleolar localization domain derived from the HIV tat gene, 56 and (3) the RFP coding sequence.
rAAV vector packaging, purification, and titration Recombinant AAV-2 and AAV-5 vectors were packaged using adenovirus 5 (Ad5) to provide helper functions, in combination with the trans-acting AAV factors supplied by pAd8 and 5RCB, respectively, as previously described. 4, 12, 17, 19, 24, 46, 55 Briefly, semiconfluent 293 cells were infected by Ad5 at a multiplicity of infection (MOI) of 3-5 and then cotransfected with 18 mg of AAV vector plasmid and 6 mg of helper plasmid, using a calcium phosphate precipitation method. At 3 days post-transfection, cells were harvested and subjected to four freeze-thaw cycles to release the cell-associated virions. Residual Ad5 was inactivated by heating at 561C for 30 min, and any remaining plasmid DNA was removed by treatment with 25 U of RNase-free DNase (Promega, Madison, WI, USA; cat. no. M6101) per milliliter at 371C for 60 min. Viral vector preparations were purified by overnight dialysis at 41C against Dulbecco's modified Eagle's medium (BioWhittaker, Walkersville, MD, USA; cat. no. 12-604F), using Slide-A-Lyzer 10 K MWCO dialysis cassettes from Pierce (Rockford, IL, USA; cat. no. 66425), when the reporter gene was lacZ and Spectra/Por CE DispoDialyzers 50K MWCO from Spectrum (Laguna Hills, CA, USA; cat. no. 135 522) when the reporter gene was RFP.
Titers of the viral vector preparations were screened by real-time PCR as previously described 57 using a Prism 7700 Sequence Detector System from Perkin-Elmer (PE)-Applied Biosystems (Foster City, CA, USA) and the TaqMan Universal PCR Master Mix (PE-Applied Biosystems; cat. no. 4304437). Titers estimated by this method were between 10 10 and 10 11 transgene copies per milliliter, with no consistent significant differences between the titers of rAAV-2 and rAAV-5 preparations. The primer sets and fluorescent probes were purchased from PE-Applied Biosystems and Metabion (Martinsried, Targeting transgene expression to microglia with AAV M Cucchiarini et al Germany), respectively. Titer estimations obtained by this methodology were consistently at least one log higher than functional titers obtained by serial dilution of vector preparations on 293 cells. It has been estimated that the ratio of virus particles to functional vectors is about 500-1.
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In vitro vector transductions were performed by incubating the target cells with rAAV in a limiting amount of serum-free medium for 90 min at 371C. Cells were then cultured in appropriate medium with serum.
Analyses of transgene expression
Detection of b-galactosidase (b-gal) activity in cells transduced with lacZ-expressing vectors was performed by X-Gal staining using a standard method. 59 For the evaluation of fluorescence in cells exposed to RFPexpressing vectors, cells were first fixed in 2% paraformaldehyde, 23 mM NaH 2 PO 4 Á H 2 O, 77 mM Na 2 HPO 4 , pH 7.4 for 30 min at room temperature and mounted on microscope slides (Fisher Scientific; cat. no. 12-550-15) using Aqua Poly/Mount mounting medium (Polysciences, Inc., Warrington, PA, USA; cat. no. 18606). Fluorescence was then detected using a confocal microscope (Carl Zeiss LSM 410, Thornwood, NY, USA) with a 568-nm filter.
CNS injections and histology
rAAVs were injected into the brains of male SpragueDawley rats (150-200 g). Briefly, rats were anesthetized with 90 mg/kg ketamine, 10 mg/kg xylazine, and mounted on a Kopf stereotactic frame. A burr hole was drilled 3 mm left of the Bregma, and 2 ml of rAAV were injected into the striatum at a depth of 3 mm at a rate of 1 ml/min using a glass micropipette air pressure injection system. The wounds were closed with wound clips, the animals were allowed to recover, and were then returned to their cages with unlimited access to food and water. The rats were killed at different times post-treatment by CO 2 inhalation, and their brains collected. Brains were fixed overnight in freshly prepared 10% paraformaldehyde in phosphate buffer, washed with Tris buffer, and cryoprotected by immersion in 30% sucrose prior to being embedded in O.C.T. compound (Sakura/TissueTek, Torrence, CA, USA; cat. no. 4583). The tissues were sectioned at 6 mm on a cryo-microtome (Leica CM1850; Northvale, NJ, USA) and placed on microscope slides. RFP and F4/80 were detected by staining the sections with an anti-RFP monoclonal antibody (Clontech Laboratories; cat. no. 8374-2) at a 1 : 50 dilution, and a rat anti-F4/80 antibody (Serotec, Raleigh, NC, USA; cat. no. MCAP497) at a 1 : 100 dilution, respectively. Antigen reactivities were visualized using a rhodamine-conjugated goat anti-mouse (Caltag, Burlingame, CA, USA; cat. no. M30002) at 1 : 100, and a biotinylated rabbit antirat (Vector Laboratories, Burlingame, CA, USA; cat. no. BA-4000) at 1 : 150 together with FITC-conjugated streptavidin (Vector Laboratories; cat. no. SA-5001) at 1 : 200.
